
Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:
PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIES
PALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026
PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026
PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026
PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026